We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Enable Injections Introduces Mobile Monitoring and Larger Volume Capabilities to its Compact-Sized High Volume Wearable Injectors


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Enable Injections Introduces Mobile Monitoring and Larger Volume Capabilities to its Compact-Sized High Volume Wearable Injectors"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

• An Enable Wearable Injector with Bluetooth connectivity for compliance monitoring and big data capture with a mobile app

• Market leading volume capabilities: The Enable Injector is being developed to comfortably deliver up to 50 mL doses of high volume and/or viscous biologics subcutaneously

“The Enable high volume wearable injectors are engineered with the goal of increasing compliance with drug regimens by making it so easy and convenient that patients will take their prescribed biologics regularly, even the largest doses,” said Enable Injections CEO Michael D. Hooven.  

“The benefit for Bio-Pharma companies is they can get their product into clinical evaluation quicker as there is no need to spend time on additional formulation to achieve low volumes,” he added. “In addition, now pharmaceutical companies, physicians and patients can each have the tracking data they need by using a mobile app or Bluetooth connected device. The ultimate goal is that the new drug delivery technology will not only benefit patients by improving their health outcomes, but also lower costs by streamlining drug development and replacing costly hospital-based infusions.”

The announcement was made at the Partnership Opportunities in Drug Delivery (PODD) meeting in Boston, October 5-6, 2015.

Advertisement